Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02911935 · ClinicalTrials.gov registry record · Phase 2

Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II

A Phase 2 study, sponsored by Washington University School of Medicine.

Completed
Registry status
Phase 2
Development phase
200
Enrollment target

NCT02911935: Completed Phase 2 study, sponsored by Washington University School of Medicine.

NCT02911935 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 200 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02911935, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
Phase 2
Development phase
200 participants
Enrollment target

Study Summary

The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze during the preschool years.

Primary Outcome

Episodes of wheezing were captured at each of the study telephone interviews and clinic visits using the question, "Has your child's chest sounded wheezy or whistling (with and without a cold)?". A new wheezing episode was defined if at least 7 days without wheezing had been reported since the previous episode.

Interventions

  • DRUG Placebo
  • DRUG Oral azithromycin

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2016-11
Est. Completion 2021-04
Phase Phase 2

What the finished NCT02911935 record still lists

NCT02911935 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (50% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02911935 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02911935 about?

NCT02911935 is a clinical study titled "Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II". The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze during the preschool years.

What is the current status of trial NCT02911935?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2016-11. Estimated completion is 2021-04.

What interventions are being tested in trial NCT02911935?

The interventions under investigation include: Placebo (DRUG), Oral azithromycin (DRUG).

Who is sponsoring clinical trial NCT02911935?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02911935's enrollment target sits among peer trials

200 304th of 2000 higher than 1,652 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02911935, the US trial registry maintained by the National Library of Medicine. NCT02911935 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.